Nippon Shinyaku KK

4516

Equity

ISIN JP3717600005 / Valor 763041

Tokyo Stock Exchange (2024-12-27)

JPY 4,007.00+1.93%

Nippon Shinyaku KK
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Nippon Shinyaku KK is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products and functional food ingredients. The company focuses on providing innovative treatments in areas such as urology, hematology, and rare diseases, aiming to address unmet medical needs. With a commitment to improving patient outcomes, Nippon Shinyaku leverages its expertise in biotechnology and drug development to deliver effective therapeutic solutions. Additionally, the company produces functional food ingredients that contribute to health and wellness. Through its comprehensive approach to healthcare, Nippon Shinyaku strives to enhance the quality of life for patients and consumers.

Summarized from source with an LLMView SourceSector: Healthcare

Sales Revenue

In the first quarter of the fiscal year ending March 2024, Nippon Shinyaku KK reported sales revenue of 37,012 million yen. This figure increased to 73,314 million yen by the end of the second quarter. The company forecasts a total sales revenue of 157,000 million yen for the fiscal year ending March 2025.

Operating Income

Nippon Shinyaku KK's operating income for the first quarter of the fiscal year ending March 2024 was 11,163 million yen. By the second quarter, this figure rose to 20,878 million yen. The company projects an operating income of 33,000 million yen for the fiscal year ending March 2025.

Net Income

The net income attributable to owners of the parent for Nippon Shinyaku KK was 8,749 million yen in the first quarter of the fiscal year ending March 2024. This increased to 16,176 million yen by the second quarter. The forecast for net income for the fiscal year ending March 2025 is 30,000 million yen.

R&D Expenses

Research and development expenses for Nippon Shinyaku KK were 5,911 million yen in the first quarter of the fiscal year ending March 2024. By the second quarter, R&D expenses reached 12,517 million yen. The company anticipates R&D expenses to total 33,000 million yen for the fiscal year ending March 2025.

Business Outlook

Nippon Shinyaku KK's consolidated business forecast for the fiscal year ending March 2025 includes a sales revenue target of 157,000 million yen and an operating income of 33,000 million yen. The company expects a profit before tax of 33,600 million yen and a profit attributable to owners of the parent of 30,000 million yen, with basic earnings per share projected at 445.24 yen.

Summarized from source with an LLMView Source

Key figures

-19.1%1Y

-50.7%3Y

-57.5%5Y

Performance

32.7%1Y

35.9%3Y

33.2%5Y

Volatility